Insulin aspart, recombinant Subcutaneous and Ranibizumab ophthalmic
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Ranibizumab ophthalmic and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: ranibizumab ophthalmic
Brand name: Lucentis
Synonyms: Ranibizumab (ophthalmic), Ranibizumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Ranitidine
- Insulin aspart, recombinant Subcutaneous-Ranitidine Capsule
- Insulin aspart, recombinant Subcutaneous-Ranitidine Hydrochloride
- Insulin aspart, recombinant Subcutaneous-Ranitidine Injection
- Insulin aspart, recombinant Subcutaneous-Ranitidine Suspension
- Insulin aspart, recombinant Subcutaneous-Ranitidine Syrup
- Ranibizumab ophthalmic-Insulin degludec
- Ranibizumab ophthalmic-Insulin Degludec (U-100) Prefilled Pens
- Ranibizumab ophthalmic-Insulin Degludec (U-100) Vials
- Ranibizumab ophthalmic-Insulin Degludec (U-200) Prefilled Pens
- Ranibizumab ophthalmic-Insulin degludec and liraglutide
- Ranibizumab ophthalmic-Insulin degludec and liraglutide Subcutaneous